









Markets
/
Stocks
/
nasdaq-gels
/

Gelteq Ltd

GELS

1.070USD

-0.020-1.83%

Market hours （ET）Quotes delayed by 15 min

10.33MMarket Cap

LossP/E TTM



Gelteq Ltd

1.070

-0.020-1.83%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Gelteq Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Gelteq Ltd's Score

Industry at a Glance

Industry Ranking

136 / 173

Overall Ranking

564 / 4682

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Gelteq Ltd Highlights

StrengthsRisks

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a highly versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

Overvalued

The company’s latest PE is -2.15, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 105.80K shares, increasing 0.61% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Pharmaceuticals industry's average is 7.77.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Gelteq Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.62, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is -2.15, which is -6.61% below the recent high of -2.01 and -493.78% above the recent low of -12.75.

Score

Industry at a Glance

Previous score

7.62

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 136/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.70, which is lower than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 1.53 and the support level at 0.97, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.79

Change

-0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.022

Sell

RSI(14)

39.096

Neutral

STOCH(KDJ)(9,3,3)

15.629

Sell

ATR(14)

0.113

High Vlolatility

CCI(14)

-146.759

Sell

Williams %R

89.208

Oversold

TRIX(12,20)

-0.527

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.152

Sell

MA10

1.195

Sell

MA20

1.239

Sell

MA50

1.310

Sell

MA100

1.503

Sell

MA200

1.598

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Markoff (Jeffrey)

2.44M

Golik (David)

1.01M

Givoni (Nathan Jacob)

657.09K

Crestmont Pty Ltd

642.32K

Barabash Family Trust

441.00K

Szewach (Simon Hayden)

338.20K

Olyniec (Jeffrey W.)

164.81K

HRT Financial LP

44.62K

Citadel Advisors LLC

23.20K

+52.99%

Wedbush Securities, Inc.

20.00K

-61.72%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Pharmaceuticals industry's average is 5.11. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.